The disclosure provides compositions and methods for cell therapy of hPAP in humans using gene corrected and in vitro differentiated patient autologous macrophage cells. The disclosure also provides compositions in the form of a cell product and related compositions and methods for making the cell product and for direct pulmonary transplantation of same.

Compositions and methods for the treatment, prevention, or reversal of a central nervous system (CNS) injury or disorder in a patient in need that include administering a therapeutically effective amount of meningeal immune cells are disclosed. Specifically, the meningeal immune cells comprise Ly6C+ monocytes. Further disclosed are wherein the meningeal immune cells are modified to include a drug or gene therapeutic compound, and wherein the modified meningeal immune cells are configured to deliver the drug or gene therapeutic compound to the CNS of the subject via the parenchyma or meningeal tissue of the subject.

The disclosure provides methods to genetically engineer granulocyte-macrophage progenitors (GMPs) to express a chimeric antigen receptor (CAR), and uses thereof, including for cancer immunotherapy.

Genetically modified CCNT1 and XPO1 genes encoding proteins that inhibit virus infection in cells. The genetically modified CCNT1 gene encodes a protein with a C261Y substitution with respect to the human CCNT1 protein. The genetically modified XPO1 gene encodes a protein with P411T, M412V, and/or F414S substitutions with respect to the human XPO1 protein. The genetically modified CCNT1 and XPO1 genes can be introduced in cells. The cells comprising the genetically modified CCNT1 and XPO1 genes can be introduced in a subject with a virus infection to treat the infection.

Provided herein are compositions, such as, for example, CXCL 10-secreting antigen presenting cells, and methods for ultrasound-induced blood-brain bander disruption (e.g., low-intensity pulsed ultrasound (LIPU)) to treat a brain cancer in a mammalian subject.

The present invention provides macrophages genetically modified to express IL-31 or both IL-31 and a chimeric antigen receptor (CAR) for treatment of cancer. It further provides methods for treatment of cancer comprising administration of IL-31 along with genetically unmodified macrophages or genetically modified to express a CAR.

Provided herein are innate immune cells for use in therapeutic methods. Also described herein are pharmaceutical compositions comprising innate immune cells for use in the treatment of a variety of diseases including, but not limited to pathogenic infections, pulmonary diseases, inflammatory diseases, autoimmune diseases, and immunodeficiency.

Embodiments described herein relate to suppressing the immune response locally within tissue transplants and certain conditions improperly affecting the immune system using optogenetically controlled cells. More specifically, embodiments described herein provide for localized immunosuppression surrounding tissue transplants and illness locations as an alternative to systemically suppressing a patient's entire immune system. Methods include implantation of optogenetically modified immunosuppressive cells that are configured to alter their biological activity to enhance their immunosuppressive activity in response to exposure of wavelengths of light in the red and near-infrared window spectral region (620-900 nm).

The present invention relates to engineered extra-cellular vesicle internalizing receptors that have the ability to enhance uptake, processing, and presentation to T-cells of tumor-associated antigens by an antigen-presenting cell. It further relates to vectors or antigen presenting cells expressing said receptors, composition and uses thereof for the prevention and/or treatment of a cancer.

This invention provides a cell line of M2C macrophage and its applications. The cell line is derived from monocytes isolated from bone marrows and peripheral blood. The monocytes were differentiated into M2 macrophage by macrophage colony-stimulating factor (M-CSF), and then the polarization of M2C macrophage was induced by baicalin. The MERTK, PTX3, and PD-L1 expression level of the M2C macrophage are high and promote phagocytosis. Hence it can be applied to cell therapy or biological agents of immune regulation. Also, the macrophage-conditioned medium and wound dressing prepared on the M2C cell have the effects of enhancing fibroblast proliferation and angiogenesis, which can improve wound healing in medical use, and can be applied to skin care product for skin repair and rejuvenation.